The Synthesis and Evaluation of C7-Substituted α-Tetralone Derivatives as Inhibitors of Monoamine Oxidase

被引:16
作者
Legoabe, Lesetja J. [1 ]
Petzer, Anel [1 ]
Petzer, Jacobus P. [1 ,2 ]
机构
[1] North West Univ, Ctr Excellence Pharmaceut Sci, ZA-2520 Potchefstroom, South Africa
[2] North West Univ, Sch Pharm, Pharmaceut Chem, ZA-2520 Potchefstroom, South Africa
基金
芬兰科学院; 英国医学研究理事会; 新加坡国家研究基金会;
关键词
competitive; dialysis; inhibition; monoamine oxidase; reversible; alpha-tetralone; PARKINSONS-DISEASE; HUMAN-BRAIN; L-DOPA; LEVODOPA; SELEGILINE; DEPRESSION; TYRAMINE; THERAPY; AGONIST; ANALOGS;
D O I
10.1111/cbdd.12508
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Based on a previous report that -tetralone (3,4-dihydro-2H-naphthalen-1-one) is a promising scaffold for the design of highly potent inhibitors of the enzyme, monoamine oxidase, the present study investigates the monoamine oxidase inhibitory properties of a synthetic series of fifteen C7-substituted -tetralone derivatives. Arylalkyloxy substitution on C7 of the -tetralone moiety yielded compounds with high inhibition potencies toward the human monoamine oxidase-B isoform with all compounds possessing IC50 values in the submicromolar range (0.00089-0.047m). The C7-substituted -tetralones also were highly potent monoamine oxidase-A inhibitors with thirteen (of fifteen) compounds possessing IC50 values in the submicromolar range (0.010-0.741m). The -tetralones were, however, in each instance selective for monoamine oxidase-B over the monoamine oxidase-A isoform. Dialyses of enzyme-inhibitor mixtures show that, while a representative inhibitor acts as a reversible monoamine oxidase-A inhibitor, inhibition of monoamine oxidase-B is not readily reversed by dialysis. Using a molecular modeling approach, possible binding orientations and interactions of selected -tetralones with the active sites of the monoamine oxidases are also proposed. This study suggests that C7-substituted -tetralones are promising monoamine oxidase inhibitors and may represent lead compounds for the development of therapies for Parkinson's disease and depression.
引用
收藏
页码:895 / 904
页数:10
相关论文
共 32 条
[1]   Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs [J].
Binda, Claudia ;
Wang, Jin ;
Pisani, Leonardo ;
Caccia, Carla ;
Carotti, Angelo ;
Salvati, Patricia ;
Edmondson, Dale E. ;
Mattevi, Andrea .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (23) :5848-5852
[2]   Moclobemide: Therapeutic use and clinical studies [J].
Bonnet, U .
CNS DRUG REVIEWS, 2003, 9 (01) :97-140
[3]   Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems [J].
Carlsson, A .
JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (5-6) :777-787
[4]  
COLLINS G G S, 1970, Nature (London), V225, P817, DOI 10.1038/225817a0
[5]  
Da Prada M, 1988, J Neural Transm Suppl, V26, P31
[6]  
Costa FHD, 2012, ARQ NEURO-PSIQUIAT, V70, P617
[7]  
Fahn S, 2004, NEW ENGL J MED, V351, P2498
[8]   Monoamine oxidase-B inhibition in the treatment of Parkinson's disease [J].
Fernandez, Hubert H. ;
Chen, Jack J. .
PHARMACOTHERAPY, 2007, 27 (12) :174S-185S
[9]  
Finberg JPM, 1998, J NEURAL TRANSM-SUPP, P279
[10]   THE EFFECT OF AGE ON THE ACTIVITY AND MOLECULAR-PROPERTIES OF HUMAN-BRAIN MONOAMINE-OXIDASE [J].
FOWLER, CJ ;
WIBERG, A ;
ORELAND, L ;
MARCUSSON, J ;
WINBLAD, B .
JOURNAL OF NEURAL TRANSMISSION, 1980, 49 (1-2) :1-20